Jefferies Group acquired 1.39M Spyre Therapeutics shares worth $23.6M. That's 0.40% of their equity portfolio (56th largest holding). The investor owns 1.59% of the outstanding Spyre Therapeutics stock. The investor's estimated purchase price is $38.2M, resulting in a loss of 38%.